Selection of Mutations in HIV-1 Nucleocapsid and Integrase in Individuals Living with HIV Experiencing Virologic Failure After Initiating or Switching to Tenofovir-Lamivudine-Dolutegravir

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Tenofovir-lamivudine-dolutegravir (TLD) is an effective, single-tablet ART regimen but the causes of virologic failure that can occur despite adherence to TLD are incompletely understood, especially when resistance mutations in integrase (IN) are absent. Noncanonical resistance mutations in nucleocapsid (NC) have been selected in cell culture and are associated with decrease...

Topics

Open a Topic to create a Post that cites this publication.

• Drug Resistance, Viral
• Heterocyclic Compounds, 3-Ring
• HIV-1
• HIV/AIDS drug development and treatment
• HIV Infections
• HIV Integrase Inhibitors
• HIV Research and Treatment
• Mutation

Identifiers and source

Literature Corpus work

e851c0f7-50f2-55d8-9f43-a39b568c00e1

DOI

10.64898/2026.07.02.26356352